{"entity":{"id":"bhv-1530","kind":"drug","name":"BHV-1530","aka":["AMB302"],"tldr":"BHV-1530 is an experimental antibody-drug conjugate from Biohaven, in phase 1 trials for urothelial cancer and other solid tumours.","summary":"BHV-1530 is an antibody-drug conjugate from Biohaven. An antibody-drug conjugate directed at FGFR3. Biohaven's pipeline lists it in phase 1b for urothelial cancer and other tumours; the phase 1 study NCT06874335 tests it alone and with cemiplimab. Whether it works in people has not been established.","status":"phase-1","asOf":"2026-11-04","links":[{"label":"Biohaven pipeline","url":"https://www.biohaven.com/pipeline/"},{"label":"ClinicalTrials.gov NCT06874335","url":"https://clinicaltrials.gov/study/NCT06874335"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["fgfr3-receptor"],"drugs":[],"companies":["biohaven"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06874335"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo startup monitors, investor portfolios (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-04"},"code":"BHV-1530","modality":"Antibody-drug conjugate","mechanism":"An antibody-drug conjugate directed at FGFR3.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/bhv-1530/","neighbours":{"target":[{"id":"fgfr3-receptor","kind":"target","name":"FGFR3","route":"/targets/fgfr3-receptor/"}],"company":[{"id":"biohaven","kind":"company","name":"Biohaven","route":"/companies/biohaven/"}],"trial":[{"id":"nct06874335","kind":"trial","name":"A Phase 1 Study of BHV-1530 in Advanced Solid Tumors","route":"/trials/nct06874335/"}]}}